What is Price-to-Sales Ratio (P/S)?

The price-to-sales ratio (P/S) is a valuation multiple that compares a company's market capitalization to its total revenue over the trailing twelve months (TTM). It is calculated by dividing market cap by TTM revenue, or equivalently, by dividing the stock price by revenue per share. A P/S of 2.0x means investors are paying $2 for every $1 of annual revenue the company generates.

P/S is especially valuable for evaluating companies that are not yet profitable, which is common in the cannabis industry where many operators are still scaling their businesses. Unlike the price-to-earnings (P/E) ratio, P/S remains meaningful even when a company has negative earnings. This makes it the go-to valuation metric for growth-stage cannabis companies that are reinvesting heavily to capture market share.

A lower P/S ratio generally suggests a stock is cheaper relative to its revenue, but context matters enormously. Companies with higher revenue growth rates, better margins, or stronger competitive moats typically command higher P/S multiples because investors expect future profitability to justify the premium. Comparing P/S ratios across different industries can be misleading because profit margins vary widely by sector.

When analyzing cannabis stocks, it is useful to compare P/S ratios within peer groups: MSOs to other MSOs, LPs to other LPs, and so on. A cannabis MSO trading at 1.5x revenue while its peers trade at 3.0x could represent either a bargain or a warning sign depending on the company's growth trajectory, margin profile, and balance sheet health.

When analyzing price-to-sales ratio (p/s) for cannabis stocks, investors must account for industry-specific factors that can distort this metric compared to other sectors. Section 280E tax treatment dramatically impacts profitability metrics for US plant-touching operators, potentially making profitable companies appear unprofitable on paper. Additionally, the rapid growth phase of the cannabis industry means that historical comparisons within the sector itself may be limited.

Cannabis companies often report both GAAP and adjusted financial figures, and price-to-sales ratio (p/s) may differ significantly between the two. Investors should understand which version is being presented and what adjustments have been made. Comparing price-to-sales ratio (p/s) across cannabis sub-sectors (MSOs vs. LPs vs. ancillary companies) requires additional context because each faces different regulatory environments, tax treatments, and competitive dynamics.